Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
small cell lung cancer
Biotech
BioNTech posts survival data behind bispecific's phase 3 push
BioNTech saw 16.8 months OS in a Chinese phase 2 trial, suggesting the candidate could set a new benchmark in a space served by AstraZeneca and Roche.
Nick Paul Taylor
Mar 28, 2025 8:00am
Chasing Merck, BioNTech, DualityBio post first data on ADC
Dec 6, 2024 9:07am
Merck, Daiichi repeat early success in small cell lung cancer
Sep 9, 2024 10:27am
Merck stops phase 3 TIGIT trial in lung cancer for futility
Aug 8, 2024 7:49am
Daiichi pays Merck $170M to form lung cancer T-cell engager pact
Aug 6, 2024 8:17am
Novartis entrenches into radiopharma with $1B Mariana buy
May 2, 2024 7:00am
